Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy-Reference-Cited by-同舟云学术

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Published:2018-09-19 Issue:12 Volume:17 Page:2530-2542
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Gomes Bruno,Driessens Gregory,Bartlett Derek,Cai Danying,Cauwenberghs Sandra,Crosignani Stefano,Dalvie Deepak,Denies Sofie,Dillon Christopher P.,Fantin Valeria R.,Guo Jie,Letellier Marie-Claire,Li Wenlin,Maegley Karen,Marillier Reece,Miller Nichol,Pirson Romain,Rabolli Virginie,Ray Chad,Streiner Nicole,Torti Vince R.,Tsaparikos Konstantinos,Van den Eynde Benoit J.,Wythes Martin,Yao Li-Chin,Zheng Xianxian,Tumang Joseph,Kraus Manfred

Funder

Pfizer (Pfizer Inc.)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Rational design of 2-benzylsulfinyl-benzoxazoles as potent and selective indoleamine 2,3-dioxygenase 1 inhibitors to combat inflammation;Bioorganic Chemistry;2024-11

3. Brain macrophage senescence in glioma;Seminars in Cancer Biology;2024-09

4. Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies;Science;2024-08-23

5. Targeting amino acid-metabolizing enzymes for cancer immunotherapy;Frontiers in Immunology;2024-08-14